FindTrial
Sign In

Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05544032
Enrollment
Unknown
Registered
2022-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Graft Vs. Host Disease

Keywords

Chronic Graft Vs. Host Disease, cGVHD

Brief summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Interventions

DRUGaxatilimab

Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks

Sponsors

Incyte Corporation
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026